Nanocan Therapeutics
National Harbor, US · Founded 2020 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
DK
Dave KrasneExecutive Officer
EC
Eric C. BroylesExecutive Officer, Director
JP
Jacques P. WalkerExecutive Officer, Director
Investors · 1
Competitors · 9
by search overlapNanobiotix7 shared keywordsNanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients. The company builds on French scientific research and targets patients worldwide through disruptive treatment approaches.
Diabetes Prevention Program7 shared keywords
PatSnap7 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Integrated Nanotherapeutics Inc.6 shared keywordsIntegrated Nanotherapeutics (INT) is a preclinical-stage biotech developing antigen-specific immune tolerance therapies using lipid nanoparticles to treat autoimmune diseases such as Type 1 Diabetes, Multiple Sclerosis, and allergy. Its lead program, INT-101, targets Type 1 Diabetes, and the company also offers an LNP-based drug delivery platform for small molecules and nucleic acids.
Mapquest5 shared keywordsProvider of geographical information systems and services; acquired by America Online.
Dervan et al5 shared keywords
visit www.jnanatx.com5 shared keywordsJnana Therapeutics operates a chemoproteomics-based drug discovery platform called RAPID to identify small molecule medicines targeting protein binding sites across multiple target classes. Its pipeline focuses on therapies for phenylketonuria (PKU) and immune-mediated diseases.
ResearchGate5 shared keywords
Built In4 shared keywords
Companies competing with Nanocan Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$5.1MraisedFeb 2025 · 41 investors · BiotechnologyRule 506(b)
▶$5.1MraisedFeb 2025 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dave KrasneExecutive Officer
- Eric C. BroylesExecutive Officer, Director
- Jacques P. WalkerExecutive Officer, Director
- Offering amount
- $6.5M
- Amount sold
- $5.1M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.1MraisedAug 2020 · 6 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedAug 2020 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jacques WalkerExecutive Officer
- Eric BroylesExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $1.1M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $399.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.